News
Cue received emergency use authorization for its at-home COVID-19 test in March and went public in September.
The new funding round brings the company's valuation to $4.6 billion.
The company said the latest round brings its total raise to $47 million.
The tool uses information about pain level, condition and current medication regimen to find an effective dose of opioids.
Third-party developers can use the platform to build their own products or update instruments.
The scheme is being run in partnership with government technology firm PUBLIC.
The pair aim to make AI-enhanced diagnostics accessible beyond hospital settings.
The two companies will also collaborate on a clinical study using AI mammography.
This IPO comes roughly a year after the company closed a $25 million SPAC.
The company will cater to individuals with serious mental illness and severe depression.